LENZ Therapeutics, Inc. (LENZ)
NASDAQ (NGS) NASDAQ (NGS) Primary 
LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Yennawar - Leerink Partners Joe Catanzaro - Piper Sandler Stacy Ku - TD Cowen Jason Gerberry - Bank of America Lachlan Hanbury-Brown - William Blair Denis Reznik - Raymond James Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year End 2024 Financial Results Conference Call.
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.
LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President and CEO Shawn Olsson - CCO Marc Odrich - CMO Conference Call Participants Yigal Nochomovitz - Citi Marc Goodman - Leerink Partners Joe Catanzaro - Piper Sandler Pavan Patel - Bank of America Lachlan Hanbury-Brown - William Blair Gary Nachman - Raymond James Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call.
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
On Sunday, Corxel Pharmaceuticals and LENZ Therapeutics LENZ released topline data from the Phase 3 JX07001 trial of LNZ100 in patients with presbyopia in China.
LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate.
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024
LENZ Therapeutics (NASDAQ: LENZ ) just reported results for the first quarter of 2024. LENZ Therapeutics reported earnings per share of -$3.53.
LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President & CEO Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Pavan Patel - Bank of America Yigal Nochomovitz - Citigroup Joseph Catanzaro - Piper Sandler Marc Goodman - Leerink Lachlan Hanbury-Brown - William Blair Matthew Caufield - H. C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics Second Quarter 2024 Conference Call.
